benzilate varies from 9 to 90% in different tissues, with the highest ratios in the pons, medulla, and heart atrium. In the presence of guanyl nucleotides,
which is selective for M-l receptors, has relatively low affinity. The ratio of high-affinity
[3H]acetylcholine binding sites to total muscarinic binding sites labeled by [3H] quinuclidinyl benzilate varies from 9 to 90% in different tissues, with the highest ratios in the pons, medulla, and heart atrium. In the presence of guanyl nucleotides,
[3H] acetylcholine binding is decreased, but the extent of decrease varies from 40 to 90% in different tissues, with the largest decreases being found in the pons, medulla, cerebellum, and heart atrium. The results indicate that [3H]acetylcholine binds to high-affinity M-l and M-2 muscarinic receptors, and they suggest that most M-2 sites have high affinity for acetylcholine but that only a small fraction of M-l sites have such high affinity.
Muscarinic cholinergic receptors in brain ,and peripheral tissues have been studied extensively using radiolabeled antagonist ligands such as [3H]quinuclidinyl benzilate ([3H]QNB), [3H]N-methylscopolamine, and [3H] propylbenzilylcholine (Yamamura and Snyder, 1974; Birdsall et al., 1978; Hulme et al., 1978) . Muscarinic antagonists bind to receptors with Hill coefficients (n,) close to 1; however, muscarinic agonists compete for [3H] antagonist binding sites with shallow competition slopes (n,,< 1) which deviate from simple mass action predictions for a single class of sites (Birdsall et al., 1978) . One reasonable explanation for this is that agonists bind to multiple sites or states of muscarinic receptors with varying affinities, while most antagonists bind to the different sites or states with equal affinities (Birdsall et al., 1978) . Evidence for this was obtained using the agonist ligand [3H]oxotremorine-M (Birdsall et al., 1978) .
Studies of the actions of muscarinic agonists and detailed analyses of binding competition curves between muscarinic agonists and [3H]antagonists have led to the concept of muscarinic receptor subtypes (Rattan and Goyal, 1974; Goyal and Rattan, 1978; Birdsall et al., 1978) . This concept was reinforced by the discovery of the selective actions and binding properties of the antagonist pirenzepine (Hammer et al., 1980; Hammer and Giachetti, 1982; Watson et al., 1983; Luthin and Wolfe, 1984 ). An evolving classification scheme for these muscarinic receptors divides them into M-l and M-2 subtypes (Goyal and Rattan, 1978 ; for reviews, see Hirschowitz et al., 1984) . Although details of the distinctions between M-l and M-2 receptor subtypes are still emerging, this classification offers a convenient framework in which to compare the binding properties of ligands.
The M-l subtype has high affinity for pirenzepine and appears to be the prevalent muscarinic receptor in brain areas such as cerebral cortex, corpus striatum, and hippocampus, as well as in sympathetic ganglia. The M-2 subtype has relatively much lower affinity for pirenzepine and is found in high proportions in brain areas such as pons, medulla, and cerebellum, as well as in heart atrium and the ileum of the small intestine. In addition, guanyl nucleotides affect the binding of agonists at muscarinic receptors, and this effect appears to be greatest in tissues with a high proportion of M-2 sites. This is consistent with evidence that some muscarinic receptors are coupled to adenylate cyclase and inhibit the formation of CAMP (Murad et al., 1962; Brown, 1979) . In fact, the differences between M-l and M-2 receptor subtypes could derive largely from the effector mechanisms to which they are coupled.
Attempts to measure muscarinic cholinergic receptor binding sites with [3H]acetylcholine ([3H]ACh) have generally met with very limited success, due to high nonspecific binding, low specific binding, and low specific radioactivity of the available ligand.4 We have circumvented these technical difficulties by utilizing [3H]ACh of high specific radioactivity and an assay procedure which minimizes nonspecific binding. Since in brain [3H]ACh also binds to nicotinic cholinergic receptor sites (Schwartz et al., 1982) we have carried out the assay for muscarinic sites in the presence of a saturating concentration of cytisin, a nicotinic agonist. Under conditions of the assay, [3H]ACh binds to sites with the characteristics of muscarinic $cholinergic receptor agonist recognition sites in brain and peripheral tissues. The purpose of this study was to characterize the kinetics of binding, pharmacology, anatomical distribution, and regulation of these sites. Binding assays. Tissues were homogenized with a Brinkmann Polytron in 50 mM Tris-HCI buffer containing 120 mM NaCI, 5 mM KCI, 1 mM MgClp, and 2 mM CaC12 (pH 7.4 at 25°C). The tissue homogenates were washed twice by centrifugation at 48,000 x g for 10 mm with intermediate homogenization in fresh buffer. The final tissue pellet was resuspended in buffer containing 100 PM diisopropyl fluorophosphate (DFP) to inhibit cholinesterases and 1.5 PM cytisin to occupy nicotinic receptors.
Materials and Methods
Routinely, the binding assays were initiated by the addition of tissue homogenate (5 to 7 mg of original weight = 250 to 450 pg of protein) to tubes containing buffer and [3H]ACh. In pharmacological studies, drugs were dissolved in buffer and added to the tubes before the tissue. Total volume of the reaction mixture was 500 ~1, and all assays were run in triplicate. Nonspecific binding was measured in parallel in the presence of 1.5 PM atropine. The reaction mixtures were incubated at 25°C for 60 min and were then filtered under reduced pressure through Whatman GF/C filters which had been wet with buffer containing 0.05% polyethyleneimine to eliminate displaceable binding to the filters (Schwartz et al., 1982) . The filters were washed 3 times with 4-ml aliquots of cold buffer, placed in vials to which Liquiscint scintillation fluid was added, and counted by liquid scintillation spectrometry at a counting efficiency of 37%. (Fig. 1, a and b) . The Hill coefficient (nH) of the saturation isotherm was 1 .Ol k 0.01 (Fig. lc) , indicating an absence of cooperativity and that, over this concentration range, [3H]ACh was binding to a single class of sites.
At a [3H]ACh concentration of 30 nM, specific binding to 7 mg of cerebral cortex (400 pg protein) was approximately 10,000 dpm and represented 65 to 70% of total binding (Fig. la) . Specific binding was linear between 2 and 20 mg of cortex tissue, and no specific binding was detected in tissue which had been placed in a boiling water bath for 5 min prior to assay. In the absence of a cholinesterase inhibitor, specific binding of [3H]ACh could not be detected. In the presence of 100 PM DFP, nonspecific binding was decreased, and specific binding was increased. Concentrations of DFP as high as 1 mM did not interfere with the assay. The rates of association and dissociation were rapid. At 25"C, the half-time (f,& for association was approximately 40 set, and the binding reached equilibrium within 30 min (Fig. 2a) . The f,,2 for dissociation was approximately 30 set, and the dissociation was essentially complete within 60 min (Fig. 2b) . The rate constants for association (k,) and dissociation (k-,) were determined graphically to be 0.034 nM-' . min-' and 1.04 min-', respectively (Fig. 2, insets) . The kinetic dissociation constant determined by the ratio k-,/k, was 31 nM, in close agreement with the Kd determined by equilibrium studies. At 0°C the flj2 for dissociation was 2 min and, consistent with this slower dissociation, the equilibrium Kd for [3H]ACh binding in cortex at 0" was 16.3 f 1 .O nM (data not shown).
Subcellular location. In subcellular distribution studies, binding was measured in the myelin, synaptosomal, and mitochondrial fractions of cerebral cortex and compared with the binding in the total homogenate. These studies indicated that [3H]ACh binding sites were located primarily within the synaptosomal and mitochondrial fractions (Table I) . This subcellular distribution of [3H]ACh binding sites was similar to that of [3H]QNB binding sites (Table I) . Pharmacological characteristics. The pharmacological characteristics of the [3H]ACh binding site in cerebral cortex were determined by measuring the inhibition of binding by drugs (Table II and Fig. 3 ). Muscarinic cholinergic drugs were potent inhibitors of binding, whereas neither nicotinic drugs, cholinesterase inhibitors, nor hemicholinium3 competed effectively for the site (Table II and Fig. 3 ). In particular, cytisin, which routinely was present in the assay at a concentration of 1.5 PM, did not decrease binding at concentrations Up t0 100 PM.
In general, muscarinic antagonists were more potent than agonists All of the agonists and most of the antagonists competed for the [3H]ACh binding sites with Hill coefficients close to 1 (Table II) . Oxotremorine was the most potent agonist tested, while bethanechol was 50 to 100 times less potent, and choline was practically inactive (Table II) . The antagonists (-)QNB, atropine, scopolamine, and dexetimide had I& values between 1 and 7 nM (Table II) . Levetimide, the pharmacologically inactive enantiomer of dexetimide, was nearly 2000 times less potent in competing for [3H]ACh binding sites (Table  II and Fig. 2 ) indicating a high degree of stereospecificity of the site. Interestingly, pirenzepine, a muscarinic antagonist that is relatively selective for the M-l subtype of muscarinic receptor (Hammer and Giachetti, 1982; Watson et al., 1983 ) competed for the [3H]ACh site in brain with a shallow Hill slope and relatively low potency (Table II and Fig. 3 ). In fact, pirenzepine was approximately 12 times more potent in competing for [3H]QNB binding sites than for [3H]ACh binding sites in cortex (Fig. 4) . (Table Ill) . Within the CNS, the binding was highest in the cerebral cortex, pons, medulla, and thalamus and lowest in the cerebellum, olfactory tubercle, and spinal cord. Among the peripheral tissues examined, specific binding was found in the heart atria and ventricles, pituitary gland, ileum of the small intestine, bronchial tissue, submandibular gland, and parotid gland (Table Ill) . Very little specific binding was detected in liver, kidney, or testes.
Saturation studies of [3H]ACh binding in several regions of brain and in heart atrium indicated that the Kd in most of the tissues was between 25 and 35 nM, but the Kd values in the hippocampus and striatum were consistently higher (Table IV) . The Hill coefficients in 0 all of the tissues examined were close to 1 (Table IV Yamamura and Snyder, 1974; Birdsall et al., 1978) . This is to a much greater extent in the medulla, pons, cerebellum, and consistent with previous reports of high potencies of agonists in atrium than in the cerebral cortex, striatum, or hippocampus (Fig 5. competing for muscarinic sites labeled by the agonists [3H]o~o-and Table V) ; but in all tissues, the fraction of sites that was affected tremorine-M (Birdsall et al., 1978) and [3H]cis-methyldioxolane (Ehlert by the nucleotide displayed similar high sensitivity to Gpp(NH)p, with et al., 1980). In contrast, the potencies of most of the antagonists in a half-maximal effect at 0.2 to 0.7 PM. 
Discussion
The studies presented here indicate that [3H]ACh, at concentrations between 2 and 300 nM, specifically labels and saturates a muscarinic cholinergic recognition site in brain and peripheral tissues. In contrast to the complex kinetics derived from studies of agonist competition for [3H]antagonist binding sites, the kinetics of [3H]ACh binding appear to be much simpler and to follow mass action predictions for a single site. This difference is probably related to the use of [3H]ACh, which presumably labels the agonist recognition site of the muscarinic receptor molecule. Although muscarinic antagonists clearly label the same receptor molecule and are potent inhibitors of [3H]ACh binding (see Table II (Table II; see also, Yamamura and Snyder, 1974; Birdsall et al., 1978) . In addition, ACh and most of the other agonists tested compete for [3H]ACh binding sites with Hill coefficients close to 1, whereas most of these agonists compete for [3H]antagonist binding sites with Hill coefficients significantly less than 1 (Birdsall et al., 1978) . These differences are unlikely to be due to agonist-induced conversion of the site to a desensitized state with high affinity for ACh, because the I& of ACh in competing for [3H]antagonist binding sites in rat brain is 2 to 5 PM (Yamamura and Snyder, 1974; Birdsall et al., 1978) , indicating that even in the presence of high concentrafions of ACh, the antagonist binding site does not appear to convert to a state with high affinity for agonists.
The M-l selective antagonist pirenzepine is more than 100 times less potent than the other antagonists tested in competing for is highest in the medulla, pons, and cerebellum, brain areas which are thought to contain a high proportion of the M-2 subtype of muscarinic receptor (Watson et al., 1983; Luber-Narod and Potter, 1982) . Similarly, in the heart atrium, a tissue in which the M-2 subtype of receptor predominates (Watson et al., 1983) , the number of [3H]ACh binding sites represents a large proportion of the number of [3H]QNB sites. Thus, consistent with the low affinity of pirenzepine, the distribution of the [3H]ACh binding site is similar to that described for M-2 receptors.
The reduction of [3H]ACh binding by guanyl nucleotides is most pronounced (80 to 90%) in the medulla, pons, cerebellum, and atrium, tissues rich in M-2 receptors. This is consistent with previous studies which found that guanyl nucleotides reduced the potency of agonists in competing for [3H] antagonist binding sites in these tissues (Berrie et al., 1979; Rosenberger et al., 1980; Sokolovsky et al., 1980) . In contrast, in the cerebral cortex, hippocampus, and striatum, the maximum reduction of [3H]ACh binding by Gpp(NH)p was approximately 50%, indicating a more obvious heterogeneity 
